Survival for metastatic colorectal cancer in the bevacizumab era: A population-based analysis

Daniel J. Renouf, Howard J. Lim, Caroline Speers, Diego Villa, Sharlene Gill, Charles Blanke, Susan E. O'Reilly, Hagen Kennecke

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Background: As of 2006, bevacizumab was available for the treatment of metastatic colorectal cancer (mCRC) in British Columbia (BC). This study compares survival between referred patients diagnosed with mCRC in 2003/2004 (pre-bevacizumab era) and 2006 (bevacizumab era). Patients and Methods: The BC cancer agency (BCCA) is a cancer network treating approximately 60% of patients with mCRC in BC. For this study, all patients in the BCCA diagnosed with mCRC in 2003/2004 and 2006 were included. The primary objective was to compare overall survival (OS) between the 2 cohorts. Results: One thousand four hundred seventeen patients were included: 969 from 2003/2004, and 448 from 2006. Between 2003/2004 and 2006, the proportion of patients treated with systemic therapy for mCRC increased (61.1% to 67.6%; P = .02). The only significant difference in treatment between the cohorts was in the proportion of patients who received bevacizumab (5.9% to 30.6%; P <.001). Median OS significantly differed between the 2 cohorts (13.8 to 17.3 months; P = .001). Median OS for patients who received systemic therapy increased (18.6-23.6 months; P <.001). Median OS for patients who did not receive systemic therapy was unchanged (6.1-5.9 months; P = .65). Conclusion: In this population-based study, median OS for mCRC significantly increased between 2003/2004 and 2006. An increase in the proportion of patients treated with systemic therapy, and the addition of bevacizumab to chemotherapy, seem to have contributed to this improvement in survival.

Original languageEnglish (US)
Pages (from-to)97-101
Number of pages5
JournalClinical Colorectal Cancer
Volume10
Issue number2
DOIs
StatePublished - 2011
Externally publishedYes

Fingerprint

Colorectal Neoplasms
Survival
Population
British Columbia
Therapeutics
Bevacizumab
Neoplasms
Drug Therapy

Keywords

  • Bevacizumab
  • Chemotherapy
  • Colorectal cancer

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology

Cite this

Survival for metastatic colorectal cancer in the bevacizumab era : A population-based analysis. / Renouf, Daniel J.; Lim, Howard J.; Speers, Caroline; Villa, Diego; Gill, Sharlene; Blanke, Charles; O'Reilly, Susan E.; Kennecke, Hagen.

In: Clinical Colorectal Cancer, Vol. 10, No. 2, 2011, p. 97-101.

Research output: Contribution to journalArticle

Renouf, DJ, Lim, HJ, Speers, C, Villa, D, Gill, S, Blanke, C, O'Reilly, SE & Kennecke, H 2011, 'Survival for metastatic colorectal cancer in the bevacizumab era: A population-based analysis', Clinical Colorectal Cancer, vol. 10, no. 2, pp. 97-101. https://doi.org/10.1016/j.clcc.2011.03.004
Renouf, Daniel J. ; Lim, Howard J. ; Speers, Caroline ; Villa, Diego ; Gill, Sharlene ; Blanke, Charles ; O'Reilly, Susan E. ; Kennecke, Hagen. / Survival for metastatic colorectal cancer in the bevacizumab era : A population-based analysis. In: Clinical Colorectal Cancer. 2011 ; Vol. 10, No. 2. pp. 97-101.
@article{df7a86a9bb4d4f1cb2f15390458948d0,
title = "Survival for metastatic colorectal cancer in the bevacizumab era: A population-based analysis",
abstract = "Background: As of 2006, bevacizumab was available for the treatment of metastatic colorectal cancer (mCRC) in British Columbia (BC). This study compares survival between referred patients diagnosed with mCRC in 2003/2004 (pre-bevacizumab era) and 2006 (bevacizumab era). Patients and Methods: The BC cancer agency (BCCA) is a cancer network treating approximately 60{\%} of patients with mCRC in BC. For this study, all patients in the BCCA diagnosed with mCRC in 2003/2004 and 2006 were included. The primary objective was to compare overall survival (OS) between the 2 cohorts. Results: One thousand four hundred seventeen patients were included: 969 from 2003/2004, and 448 from 2006. Between 2003/2004 and 2006, the proportion of patients treated with systemic therapy for mCRC increased (61.1{\%} to 67.6{\%}; P = .02). The only significant difference in treatment between the cohorts was in the proportion of patients who received bevacizumab (5.9{\%} to 30.6{\%}; P <.001). Median OS significantly differed between the 2 cohorts (13.8 to 17.3 months; P = .001). Median OS for patients who received systemic therapy increased (18.6-23.6 months; P <.001). Median OS for patients who did not receive systemic therapy was unchanged (6.1-5.9 months; P = .65). Conclusion: In this population-based study, median OS for mCRC significantly increased between 2003/2004 and 2006. An increase in the proportion of patients treated with systemic therapy, and the addition of bevacizumab to chemotherapy, seem to have contributed to this improvement in survival.",
keywords = "Bevacizumab, Chemotherapy, Colorectal cancer",
author = "Renouf, {Daniel J.} and Lim, {Howard J.} and Caroline Speers and Diego Villa and Sharlene Gill and Charles Blanke and O'Reilly, {Susan E.} and Hagen Kennecke",
year = "2011",
doi = "10.1016/j.clcc.2011.03.004",
language = "English (US)",
volume = "10",
pages = "97--101",
journal = "Clinical Colorectal Cancer",
issn = "1533-0028",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Survival for metastatic colorectal cancer in the bevacizumab era

T2 - A population-based analysis

AU - Renouf, Daniel J.

AU - Lim, Howard J.

AU - Speers, Caroline

AU - Villa, Diego

AU - Gill, Sharlene

AU - Blanke, Charles

AU - O'Reilly, Susan E.

AU - Kennecke, Hagen

PY - 2011

Y1 - 2011

N2 - Background: As of 2006, bevacizumab was available for the treatment of metastatic colorectal cancer (mCRC) in British Columbia (BC). This study compares survival between referred patients diagnosed with mCRC in 2003/2004 (pre-bevacizumab era) and 2006 (bevacizumab era). Patients and Methods: The BC cancer agency (BCCA) is a cancer network treating approximately 60% of patients with mCRC in BC. For this study, all patients in the BCCA diagnosed with mCRC in 2003/2004 and 2006 were included. The primary objective was to compare overall survival (OS) between the 2 cohorts. Results: One thousand four hundred seventeen patients were included: 969 from 2003/2004, and 448 from 2006. Between 2003/2004 and 2006, the proportion of patients treated with systemic therapy for mCRC increased (61.1% to 67.6%; P = .02). The only significant difference in treatment between the cohorts was in the proportion of patients who received bevacizumab (5.9% to 30.6%; P <.001). Median OS significantly differed between the 2 cohorts (13.8 to 17.3 months; P = .001). Median OS for patients who received systemic therapy increased (18.6-23.6 months; P <.001). Median OS for patients who did not receive systemic therapy was unchanged (6.1-5.9 months; P = .65). Conclusion: In this population-based study, median OS for mCRC significantly increased between 2003/2004 and 2006. An increase in the proportion of patients treated with systemic therapy, and the addition of bevacizumab to chemotherapy, seem to have contributed to this improvement in survival.

AB - Background: As of 2006, bevacizumab was available for the treatment of metastatic colorectal cancer (mCRC) in British Columbia (BC). This study compares survival between referred patients diagnosed with mCRC in 2003/2004 (pre-bevacizumab era) and 2006 (bevacizumab era). Patients and Methods: The BC cancer agency (BCCA) is a cancer network treating approximately 60% of patients with mCRC in BC. For this study, all patients in the BCCA diagnosed with mCRC in 2003/2004 and 2006 were included. The primary objective was to compare overall survival (OS) between the 2 cohorts. Results: One thousand four hundred seventeen patients were included: 969 from 2003/2004, and 448 from 2006. Between 2003/2004 and 2006, the proportion of patients treated with systemic therapy for mCRC increased (61.1% to 67.6%; P = .02). The only significant difference in treatment between the cohorts was in the proportion of patients who received bevacizumab (5.9% to 30.6%; P <.001). Median OS significantly differed between the 2 cohorts (13.8 to 17.3 months; P = .001). Median OS for patients who received systemic therapy increased (18.6-23.6 months; P <.001). Median OS for patients who did not receive systemic therapy was unchanged (6.1-5.9 months; P = .65). Conclusion: In this population-based study, median OS for mCRC significantly increased between 2003/2004 and 2006. An increase in the proportion of patients treated with systemic therapy, and the addition of bevacizumab to chemotherapy, seem to have contributed to this improvement in survival.

KW - Bevacizumab

KW - Chemotherapy

KW - Colorectal cancer

UR - http://www.scopus.com/inward/record.url?scp=79959338988&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959338988&partnerID=8YFLogxK

U2 - 10.1016/j.clcc.2011.03.004

DO - 10.1016/j.clcc.2011.03.004

M3 - Article

C2 - 21859560

AN - SCOPUS:79959338988

VL - 10

SP - 97

EP - 101

JO - Clinical Colorectal Cancer

JF - Clinical Colorectal Cancer

SN - 1533-0028

IS - 2

ER -